Bullfrog AI Holdings Inc (BFRG)
NASDAQHealth CareMedical - Healthcare Information ServicesSnapshot 2026-09-09
$0.49+2.07%
Close 2026-09-09 · 1-day change
NASDAQHealth CareMedical - Healthcare Information ServicesSnapshot 2026-09-09
Warn: Primary pillar under pressure — Regain Nasdaq compliance with listing rules: bid price $0.49 vs $1.00 target.
Bullfrog AI is working to regain Nasdaq compliance after recent delisting risks. The company secured a feasibility agreement with a global pharma firm to apply AI in drug discovery. This deal could drive future revenue growth from near zero to $5.25 million by 2027. CEO compensation increased, signaling management commitment.
Bullfrog AI remains loss-making with negative EPS of -$0.44 expected in 2026 and -$0.21 in 2027. The company faces ongoing regulatory risks from Nasdaq compliance issues. Revenue is currently negligible and growth is uncertain. The recent 39.8% stock drawdown reflects market doubts about turnaround progress.
The stock price is about 0.2% below our $0.70 fair value, reflecting little upside. The market prices in minimal revenue growth and continued losses. Our view is cautious given the speculative turnaround and regulatory risks.
Breaks if: EPS worsens beyond -$0.44 in 2026 or fails to improve in 2027
Breaks if: Fails to maintain Nasdaq listing compliance over next 4 quarters
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity. The current thesis state is cautious, given the company's loss-making status and volatile management.
The market seems to reflect a low level of fragility, indicating that significant negative events may not be fully priced in. However, BFRG trades at a premium compared to its peers, suggesting that investors expect some recovery or improvement.
Fundamentals may show limited improvement in the near term, as management focuses on regaining Nasdaq compliance and expanding partnerships. However, the company remains loss-making, and cash from operations is still negative.
The long-term thesis hinges on the performance of sector bellwethers and the company's ability to maintain compliance and expand its commercial partnerships. Any shifts in the broader healthcare sector could significantly impact BFRG's trajectory.
The most important moves since the prior daily snapshot.
Our read on the company is unchanged since the prior snapshot.
as of 2026-09-09
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Focus on regaining compliance with Nasdaq's minimum stockholders' equity requirement.
Breaks if: Revenue growth falls below $3.5 million in 2027
Entered into a Feasibility Agreement to apply AI tools for drug target discovery.
Over the next 1 to 3 years, BFRG's performance will depend on its execution against management priorities and external market conditions. Not investment advice.